Who are Meningococcal A+C vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MenAC conjugate vaccine, Meningococcal (vaccine), A+C Vaccine, Meningococcal ACYW135 Polysaccharide Conjugate Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/meningococcal-a-c-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Meningococcal A+C vaccine — Competitive Intelligence Brief

Meningococcal A+C vaccine (Meningococcal A+C vaccine) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C capsular polysaccharides Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Meningococcal A+C vaccine (Meningococcal A+C vaccine) — Sanofi Pasteur, a Sanofi Company. This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A and C polysaccharide antigens.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Meningococcal A+C vaccine TARGET	Meningococcal A+C vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides
MenAC conjugate vaccine	MenAC conjugate vaccine	Sanofi	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides
Meningococcal (vaccine)	Meningococcal (vaccine)	GlaxoSmithKline	marketed	Bacterial polysaccharide conjugate vaccine	Neisseria meningitidis capsular polysaccharides and outer membrane proteins
A+C Vaccine	A+C Vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsule
Meningococcal ACYW135 Polysaccharide Conjugate Vaccine	Meningococcal ACYW135 Polysaccharide Conjugate Vaccine	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	phase 3	Polysaccharide conjugate vaccine	Meningococcal serogroup A, C, Y, and W-135 polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polysaccharide conjugate vaccine class)

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · 1 drug in this class
Jiangsu Province Centers for Disease Control and Prevention · 1 drug in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Meningococcal A+C vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-a-c-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab